Engineered antibody fusion proteins for targeted disease therapy
2024-12-02
BackgroundSince the first therapeutic antibody was approved by the FAD, antibody products have developed rapidly in the drug market. Building on the success of monoclonal antibodie...
Immunomodulatory adenosine producer CD73
2024-11-29
CD73 is a 5'-nucleotidase exonuclease (NT5E). The CD73-mediated adenosine pathway converts inflammatory ATP into the immunosuppressant adenosine, which inhibits immune activation t...
Prostate specific membrane antigen PSMA
2024-11-26
Prostate-specific membrane antigen (PMSA), also known as glutamate carboxypeptidase II (GCPII) and folate hydrolase (FolH1), is a zinc-dependent metalloproteinase. PSMA is primaril...
SSTR2 is a therapeutic target for neuroendocrine tumors
2024-11-25
The somatostatin receptor (SSTR2) is a member of the G protein-coupled receptor (GPCR) superfamily, expressed in the central nervous system, particularly the hypothalamus, as well ...
Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy
2024-11-22
Fibroblast activation protein (FAP) is a serine protease with dual enzymatic activity that is overexpressed in various tumor types and in different types of cancer-associated fibro...
Efficient generation of recombinant anti-HER2 scFv with high yield and purity
2024-11-19
BackgroundHuman epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein consisting of extracellular, transmembrane, and intracellular domains. HER2 overexpression...
Fusion protein linkers: property, design and functionality
2024-11-18
BackgroundIn addition to their widespread application in biological research, such as protein purification and imaging, recombinant fusion proteins have also become a significant c...